Low-Dose Metformin as a Monotherapy Does Not Reduce Non-Small-Cell Lung Cancer Tumor Burden in Mice

Area of Science:

• Oncology
• Metabolic Disease Research
• Cancer Therapeutics

Background:

• Non-small-cell lung cancer (NSCLC) accounts for the majority of lung cancer diagnoses.
• Current treatments like chemotherapy and radiation can cause significant skeletal muscle side effects.
• Metformin, a diabetes drug, has shown anti-neoplastic properties in some cancers.

Purpose of the Study:

• To investigate the efficacy of metformin in reducing NSCLC tumor burden.
• To assess the impact of metformin on skeletal muscle health in the context of NSCLC.
• To determine if metformin can mitigate treatment-induced side effects in skeletal muscle.

Main Methods:

• A Lewis lung cancer (LL/2) model with bioluminescent tracking was established in C57BL/6J mice.
• Mice received metformin (250 mg/kg) or a control treatment twice weekly.
• Skeletal muscle tissue was analyzed for gene and protein expression related to inflammation, muscle mass, and metabolism.

Main Results:

• Metformin treatment did not significantly reduce NSCLC tumor burden in this immunocompetent mouse model.
• No significant changes were observed in tumor cell division or inflammation markers with metformin.
• Metformin administration did not lead to significant improvements in skeletal muscle health markers.

Conclusions:

• Metformin monotherapy is not effective for reducing NSCLC tumor growth in vivo.
• The drug did not demonstrate benefits for skeletal muscle health in this NSCLC model.
• Future investigations should focus on metformin as a potential adjunct therapy in combination treatments for NSCLC.